INBX - Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. , a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma.
As of May 15, 2026: spot at $111.19, ATM IV 85.2%, net GEX $228.6K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $1.72B
- Beta
- 3.89
- 52-Week Range
- 10.97-155.29
- Dividend Yield
- $0.85
- CEO
- Mark Paul Lappe
- Employees
- 156
- IPO Date
- Jun 4, 2024
- Exchange
- NASDAQ
What INBX Looks Like to Options Traders Today
IV rank of 10.2% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($228.6K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.043) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The INBX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked INBX overview questions
- What is INBX?
- INBX is the ticker symbol for Inhibrx Biosciences, Inc., a listed security. Inhibrx Biosciences, Inc. , a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Listed on NASDAQ. INBX is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the INBX options snapshot look like today?
- As of May 15, 2026, the INBX options snapshot shows spot at $111.19, ATM IV 85.2%, IV rank 10.2%, net GEX $228.6K, expected move 24.43%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are INBX's key statistics?
- Inhibrx Biosciences, Inc. (INBX) carries a market capitalization of $1.72B, beta of 3.89 relative to the broader market, 52-week range of 10.97-155.29. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does INBX belong to?
- Inhibrx Biosciences, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare INBX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the INBX data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).